plugging. At 12 months post-discharge two (17%) patients were dead; seven (58%) were not on any ventilatory support; three (25%) were continuing with tracheostomy ventilation.

**Conclusion**
Respiratory weaning from tracheostomy ventilation represent a heterogenous group which is complex with diverse aetiology and multiple comorbidities. There is a considerable variation in the LOS on ARCU and is often unpredictable. Although more than two third of patients were successfully on our unit it carries a high one year mortality. LOS is influenced by the complexity of discharge planning. We are not a dedicated weaning unit and our unit is not staffed to look after more than two tracheostomy-ventilated patients at any one time which combined with prolonged stay slows down patient flow from ICU to ARCU and from ARCU to the wards. Multidisciplinary approach and dedicated weaning units are needed that is able to look after complex needs in hospital and coordinate complex discharges.

### Abstract P131 Table 1

<table>
<thead>
<tr>
<th>Age (mean+/-SD, years)</th>
<th>56+/-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>n=8</td>
</tr>
<tr>
<td>Females</td>
<td>n=4</td>
</tr>
<tr>
<td>LOS in ICU pre tracheostomy</td>
<td>Median=4, Range=2–22</td>
</tr>
<tr>
<td></td>
<td>Mean: 9+/-6</td>
</tr>
<tr>
<td>LOS in ICU post tracheostomy</td>
<td>Median=34, Range=7–96</td>
</tr>
<tr>
<td></td>
<td>Mean 41+/-30</td>
</tr>
<tr>
<td>LOS in RCU post tracheostomy</td>
<td>Median=7, Range=1–93</td>
</tr>
<tr>
<td></td>
<td>Mean 21+/-33</td>
</tr>
</tbody>
</table>

Primary Diagnosis (n=12):

- Pneumonia 6
- Post-procedure/surgery 3
- COPD 1
- ARDS 1
- Other (Cardio-respiratory arrest) 1

**Introduction**
In isolated pneumonia, most trials show that NIV does not improve outcome, and may delay more appropriate intubation. However in pneumonia complicating COPD with acidaemic respiratory failure (AHRF), an RCT showed NIV reduced the need for intubation and conferred a survival benefit at 2 months. UK NIV guidelines state NIV is not indicated in pneumonia; whether this was intended to apply when pneumonia complicates another condition associated with a favourable response to NIV is unclear and there is substantial variation in practice. In our institution, most patients with pneumonic exacerbation of COPD (pECOPD) and AHRF receive NIV; few decline ventilation or are immediately intubated.

**Methods**
From a consecutive historical cohort of patients receiving assisted ventilation for spirometry confirmed ECOPD and AHRF, chest radiographs, electronic data and clinical notes were reviewed. The presence of consolidation was determined in the following hierarchy: attending consultant physician interpretation (to mimic reality); radiologist report; or researcher interpretation. Analysis performed using IBM SPSS; significance identified using student’s t-test, Mann Whitney U or chi-squared test for parametric, non-parametric and categorical data respectively.

**Results**
Among patients surviving to discharge, 90 day and 6 month mortality was 12.8% and 20.3% respectively in those with consolidation, compared to 12.9% and 18.4% respectively in those without.

**Discussion**
Compared to those without pneumonia, patients with pECOPD were older, had more comorbid illnesses, more severe acidaemia and greater functional limitation. In addition, AHRF was more likely to have developed after admission, despite initial medical therapies (an adverse prognostic marker). Unsurprisingly, in-hospital mortality was significantly higher in those with pECOPD, but approximately 2/3 survive to hospital discharge and post-discharge outcomes between the two groups are comparable. Coexistent consolidation is a marker of adverse acute outcome and an indication for closer monitoring but should not preclude ventilation, especially when so few are considered eligible for intubation.

**Reference**
Aim Acute hypercapnic respiratory failure (AHRF) is a medical emergency. Data from National COPD Audit Programme identified that median time from admission to Non-Invasive Ventilation (NIV) is 4.1 hours and only 42.7% of patients requiring ventilatory support receive it in under 3 hours. We utilised a novel human factors approach, reviewing AHRF case examples and undertaking multi-disciplinary discussion, to review current systems and develop interventions to improve the recognition and management of AHRF.

Methods Multi-disciplinary workshops were undertaken across emergency medicine, acute medicine, and specialist medicine to discuss case examples of AHRF. Attendees discussed the identification and management of AHRF based on the presented cases and their clinical experience. Output from the workshops and case reviews were analysed and informed the development of a Bow-Tie model that reviewed current systems in AHRF. The model identified barriers which usually facilitate effective management of these patients and threats to barriers which compromise patient care (figure 1) Interventions to address threats were developed and implemented.

Outcome/Results Interventions resulting from the multidisciplinary workshops and novel application of Bow-Tie analysis (figures 1) included: automated flag of Bow-Tie analysis on electronic Results software; AHRF management and referral checklists; multifaceted training of teams in management of AHRF (simulation training, capillary blood gases training, ward based training).

Conclusions The novel application of this human factors approach in a healthcare setting allowed the identification of specific threats and development of interventions to strengthen barriers targeted at improving patient care and reducing harm.
Poster sessions

REFERENCES

P134

AN EVALUATION OF A NEW LUNG FUNCTION TEST: TLNO IN HEALTHY SUBJECTS

A Ijaz, J Hull. Imperial College London, London, UK
10.1136/thoraxjnl-2017-210983.276

Background and Aims TLNO, transfer factor for nitric oxide, is a pulmonary function test of gas transfer. The test, in combination with carbon monoxide, allows for calculation of the alveolar membrane diffusing capacity and red blood cell conductance. This allows physicians to recognise physiologically where issues with gas transfer arise. Currently, there are very few papers looking at TLNO reproducibility in healthy subjects and none aiming with a target of 5% repeatability between efforts. This study attempts to look at the reproducibility of TLNO over 10 sessions (7 weeks total) with an intra-session repeatability of 5%. In addition, comparison of TLCO measurements between 10 and 5 s breath holds are made.

Methods 14 normal subjects were recruited and a baseline spirometry was taken and height, weight, age and sex were recorded. Subjects were asked to perform a TLCO test with 10 s breath hold followed by 10 repeated sessions of the TLNO test on different days. Measurements within 5% of each other were considered acceptable repeated Results in one session. A Bland-Altman plot and regression line were constructed to compare TLCO measures between different breath hold times. One-way repeated measures ANOVA, measurement error values, intra and inter-session variability were calculated for TLNO and TLCO recordings obtained over the 10 repeated sessions.

Results Bland-Altman plot revealed no statistically significant (p=0.783, p>0.05) difference between TLCO breath hold times. Coefficient of determination from the regression line, r^2 = 0.860. Repeated measures ANOVA revealed no significant difference for TLNO and TLCO measurements over time at p=0.374 and p=0.842 (p>0.05) respectively. Intra-session and inter-session variability for TLNO were calculated as 15.02 ml/min/mmHg and 16.12 ml/min/mmHg respectively. TLCO intra-session and inter-session variability were 4.30 ml/min/mmHg and 3.70 ml/min/mmHg. We have shown that TLNO values recorded with the shorter 5 s breath hold agree with the conventional 10 s technique. Over a 7 week period TLNO and TLCO do not change significantly and calculated session variability of TLNO over 10 sessions (7 weeks total) with an inter-session variability for TLNO were calculated as 15.02 ml/min/mmHg and 20.8 versus 37.95% (p=0.0002), anaerobic threshold 11.0 versus 12.30 ml/min/kg (p=0.0073), Peak VO2 15.1 versus 16.8 ml/min/kg (p=0.0018), smoking history 49 versus 30 pack years (p=0.0069) and BMI 26.0 versus 28.1 kg/m^2 (p=0.0024); respectively.

Conclusion The results confirmed that a significant proportion of our patients had previously undiagnosed/unrecognised airflow obstruction. As would be expected, patients with airflow obstruction had an increased peak year smoking history and a decreased BMI when compared to those without. Airflow obstruction also resulted in a decreased peak VO2 and a worsening of ventilatory limitation which has the potential to influence surgical decision making.

REFERENCES

P135

THE PREVALENCE OF UNDIAGNOSED COPD IN PATIENTS WITH AN ABDOMINAL AORTIC ANEURYSM AND ITS IMPACT ON CARDIOPULMONARY EXERCISE TESTS

L Archer, E Parke, J Shakespeare, DP Parr. University Hospitals Coventry and Warwickshire, Coventry, UK
10.1136/thoraxjnl-2017-210983.277

Introduction Cigarette smoking is a known contributing factor to the development of chronic obstructive pulmonary disease (COPD), and to the formation of an aneurysm. In addition COPD is the most important risk factor associated with abdominal aortic aneurysms (AAA). Studies have observed the relationship of COPD and AAA, demonstrating a prevalence in COPD patients of 3.7% and a 1.22–1.78 fold increased risk of AAA when compared to those without COPD.

Aims Our aim was to identify the prevalence of undiagnosed airflow obstruction in patients attending for CPET for preoperative assessment for AAA.

Methods Data from 122 patients (108 male), median age 75 years (range 65–90) with an AAA of 5 cm or more, attending between September 2014 and May 2016 were included. Spirometry, CPET, smoking history, BMI and current medication were all analysed. The patient’s clinical records were reviewed to establish any previous respiratory diagnosis.

Results 17/122 (14%) patients had a known diagnosis of COPD however 32/122 (26%) had airflow obstruction on spirometry, with only 12 of these having a diagnosis of COPD. 5 patients with a diagnosis of COPD did not demonstrate airflow obstruction. There were significant differences between those with airflow obstruction and those without for breathing reserve 20.8 versus 37.95% (p=0.0002), anaerobic threshold 11.0 versus 12.30 ml/min/kg (p=0.0073), Peak VO2 15.1 versus 16.8 ml/min/kg (p=0.0018), smoking history 49 versus 30 pack years (p=0.0069) and BMI 26.0 versus 28.1 kg/m^2 (p=0.0024); respectively.

Conclusion The results confirmed that a significant proportion of our patients had previously undiagnosed/unrecognised airflow obstruction. As would be expected, patients with airflow obstruction had an increased peak year smoking history and a decreased BMI when compared to those without. Airflow obstruction also resulted in a decreased peak VO2 and a worsening of ventilatory limitation which has the potential to influence surgical decision making.

REFERENCES
1. M Izazaga-García, 2 A Safiyou, 2 M Mooham, 2 GF Rafferty, 2t C Jolly, t Centro de Investigación Biomédica en Red en Biosanidad, Biomateriales y Nanomedicina, Barcelona, Spain, t Instituto de Biomecánica de Cataluña (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain, 3 Division of Asthma Allergy and Lung Biology, King’s College London, King’s Health Partners, London, UK, 4 Centre of Human and Aerospace Physiological Sciences, King’s College London, King’s Health Partners, London, UK
10.1136/thoraxjnl-2017-210983.278

P136

NON-INVASIVE ASSESSMENT OF DIAPHRAGM CONTRACTILITY USING SURFACE MECHANOMYOGRAPHY IN HEALTHY SUBJECTS

1 M Lezana-Garcia, 2 M Safiyou, 3 M Mooham, 2t G Rafferty, 2t C Jolly, t Centro de Investigación Biomédica en Red en Biosanidad, Biomateriales y Nanomedicina, Barcelona, Spain, 2 Instituto de Biomecánica de Cataluña (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain, 3 Division of Asthma Allergy and Lung Biology, King’s College London, King’s Health Partners, London, UK
10.1136/thoraxjnl-2017-210983.277

Characterisation of lung disease with imaging and physiology

AN EVALUATION OF A NEW LUNG FUNCTION TEST: TLNO IN HEALTHY SUBJECTS

A Ijaz, J Hull. Imperial College London, London, UK
10.1136/thoraxjnl-2017-210983.276